- Home
- CBRL vs GERN Comparison
CBRL vs GERN Comparison
Compare CBRL & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBRL
- GERN
- Stock Information
- Founded
- CBRL 1969
- GERN 1990
- Country
- CBRL United States
- GERN United States
- Employees
- CBRL N/A
- GERN N/A
- Industry
- CBRL Restaurants
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- CBRL Consumer Discretionary
- GERN Health Care
- Exchange
- CBRL Nasdaq
- GERN Nasdaq
- Market Cap
- CBRL 750.5M
- GERN 740.5M
- IPO Year
- CBRL N/A
- GERN 1996
- Fundamental
- Price
- CBRL $27.19
- GERN $1.12
- Analyst Decision
- CBRL Hold
- GERN Buy
- Analyst Count
- CBRL 10
- GERN 7
- Target Price
- CBRL $51.00
- GERN $3.00
- AVG Volume (30 Days)
- CBRL 1.5M
- GERN 8.2M
- Earning Date
- CBRL 12-05-2025
- GERN 11-05-2025
- Dividend Yield
- CBRL 3.64%
- GERN N/A
- EPS Growth
- CBRL 12.57
- GERN N/A
- EPS
- CBRL 2.06
- GERN N/A
- Revenue
- CBRL $3,483,684,000.00
- GERN $183,403,000.00
- Revenue This Year
- CBRL N/A
- GERN $166.20
- Revenue Next Year
- CBRL $3.06
- GERN $55.83
- P/E Ratio
- CBRL $13.34
- GERN N/A
- Revenue Growth
- CBRL 0.37
- GERN 522.13
- 52 Week Low
- CBRL $26.46
- GERN $1.04
- 52 Week High
- CBRL $71.93
- GERN $4.21
- Technical
- Relative Strength Index (RSI)
- CBRL 22.19
- GERN 42.30
- Support Level
- CBRL $26.46
- GERN $1.05
- Resistance Level
- CBRL $29.03
- GERN $1.28
- Average True Range (ATR)
- CBRL 1.48
- GERN 0.07
- MACD
- CBRL 0.01
- GERN -0.00
- Stochastic Oscillator
- CBRL 11.55
- GERN 28.04
About CBRL Cracker Barrel Old Country Store Inc
Cracker Barrel Old Country Store Inc operates hundreds of full-service restaurants throughout the United States. The Cracker Barrel stores consists of a restaurant with a gift shop. The restaurants serve breakfast, lunch and dinner. The gift shop offers a variety of decorative and functional items specializing in rocking chairs, holiday gifts, toys, apparel and foods.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.